Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy
Metastatic cancers during pregnancy have historically been associated to dismal outcomes, with greater rates of tumor progression in part due to diminished treatment alternatives. Immunotherapy with T-cell checkpoint inhibitors has significantly impacted the survival of several metastatic tumors. However, given their mechanism of action immune-related adverse events can occur, especially with combined immunotherapy treatments. During pregnancy, checkpoint pathways have a major role providing immune tolerance to the fetal allograft.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Mauricio Burotto, Juan G. Gormaz, Suraj Samtani, Nicolas Valls, Ricardo Silva, Carlos Rojas, Sergio Porti ño, Carlos de la Jara Source Type: research
More News: Bone Graft | Cancer | Cancer & Oncology | Immunotherapy | Melanoma | Pregnancy | Skin Cancer